**Core tip:** This is the first study to evaluate the efficacy of a low volume (5 mL) simethicone solution compared to a placebo using the McNally score to calculate the total mucosal visibility for gastroscopy. Our study showed that although earlier studies had favored higher volumes (typically 100 mL), a low volume is still effective as long as adequate premedication time of at least 30 min is allowed. Such a small volume is more suitable for patients with swallowing difficulties and the formulation had excellent patient compliance with no adverse effects.

INTRODUCTION
============

Image-enhanced gastroscopy, such as narrow-band imaging and magnifying endoscopy, can detect subtle early gastric cancer or precancerous lesions and this technology is widely available in Singapore\[[@B1]\]. However, the presence of foam, bubbles and mucus can preclude the benefits of enhanced endoscopy, as subtle mucosal lesions could be covered. In the latest Singapore Cancer Registry, more than 50% of gastric cancers were diagnosed at stage IV of disease\[[@B2]\]. This suggests that improvement is required for endoscopic detection of early gastric cancer.

Many studies have proven that premedication before gastroscopy will improve the total mucosal visibility scores. However, there is significant heterogeneity between these studies in terms of premedication time, mucosal scoring systems, primary outcome measurements and the type of medications used. Pronase, N-acetylcysteine, dimethicone, dimethylpolysiloxane and simethicone have all been demonstrated by multiple studies to be effective mucolytic and anti-foaming agents\[[@B3]-[@B11]\]. All the studies suggested that the best premedication regime is a combination of premedication (a mucolytic and an anti-foaming agent) delivered at large volumes (typically with 100 mL of water). Only one study had a treatment arm looking at small volume premedication (100 mg simethicone in 5 mL water) but this was not compared against a placebo group and the study used a unique 3-grade scoring system\[[@B11]\].

In Singapore, pronase, dimethicone and dimethylpolysiloxane are not available. N-acetylcysteine is a prescription drug and simethicone is an over-the-counter drug for infant colic used off-label for flushes during endoscopy. Premedication before gastroscopy is not routinely given to patients at all endoscopy centers due to several reasons; the perception that premedication may slow down the endoscopy schedule; the worry of adverse reactions from the medications (such as allergic reactions to N-acetylcysteine); and the worry of aspiration from drinking premedication shortly before gastroscopy. As Singapore has an aging population\[[@B12]\], it is common now to perform endoscopy on elderly patients with swallowing dysfunction. However 100 mL premedication solution before gastroscopy puts these patients at risk for aspiration, especially in the setting of moderate sedation during the procedure\[[@B13]\].

We hypothesized that if the premedication time is extended to at least 30 min, 100 mg of simethicone added to 5 mL of water will be able to mix with gastric secretions and swallowed saliva to coat a larger surface area of the gastric mucosa, and significantly improve mucosal visibility compared to placebo.

MATERIALS AND METHODS
=====================

Patient selection
-----------------

This study was conducted in Changi General Hospital in Singapore, from 14^th^ August 2015 to 19^th^ November 2015, at the outpatient gastroenterology clinics. All patients who were planned for gastroscopy as part of their management plan were asked by their respective clinic attending if they would permit a research coordinator to speak to them. If they agreed, the research coordinator would find the patient at the endoscopy listing room to obtain informed consent from the patient to participate in the study. Patients who were at least 21 years old, mentally competent to give informed consent, and scheduled for outpatient elective diagnostic gastroscopy were enrolled. Patients who were incarcerated; had prior history of surgical resection of the esophagus, stomach, or duodenum; had known hypersensitivity to simethicone; or required gastroscopy for urgent indications such as suspected gastrointestinal bleeding were all excluded from the study.

Study design
------------

This was a randomized, placebo-controlled, endoscopist-blinded study which was approved by the SingHealth Centralized Institutional Review Board (Ref: 2015/2519) and registered under clinicaltrials.gov (NCT02555228). The randomisation sequence (in blocks of 6) was computer generated by a statistician at Changi General Hospital's Clinical Trials and Research Unit (CTRU). The allocation sequence was written on separate cards as number codes and each card was placed inside a sealed opaque envelope. After a study participant registered for the elective gastroscopy, the research coordinator would open an opaque envelope outside the endoscopy suites and the patient would be allocated to either the simethicone group (100 mg of liquid simethicone added to 5 mL of water) or the placebo group (5 mL of water) based on the number written on a card.

Study participants underwent gastroscopy by 1 of the 6 accredited consultant endoscopists who were blinded to the premedication as well as the premedication time. The premedication was prepared by a research coordinator at a separate location, out of sight from the endoscopist or the endoscopy nurses inside the procedure suites. The patient was informed not to disclose the nature of the premedication to the endoscopy suite nurses or endoscopists. The research coordinator worked together with the scheduling nurse at the endoscopy center to ensure that the premedication was taken at least 30 min before the gastroscopy commenced. To confirm that the patient did not tell the endoscopist about the premedication's nature, the research coordinator followed the patient into the endoscopy suite and stood beside the patient until the procedure was over and the data collection form had been completed by the endoscopist. Premedication time was defined from the administration of the solution to the insertion of the tip of the gastroscope into the patient's mouth. All patients received topical analgesic xylocaine 10% spray to the back of their throat and intravenous midazolam with fentanyl to achieve moderate sedation during gastroscopy.

During the procedure, the endoscopist was allowed to flush additional diluted simethicone solution (1 to 3 drops of simethicone added to about 100 mL of water) down the gastroscope channel if there was obscuring gastric foam preventing a satisfactory view. The total volume of additional flushes was recorded by the endoscopy nurse assisting the procedure. After the endoscopist completed an adequate inspection of the mucosal surfaces, the endoscopist withdrew the tip of the gastroscopy up to the gastroesophageal junction and the research coordinator noted the time. The procedure time was defined as the period of time from insertion of the gastroscope to the withdrawal of the gastroscopy back to the gastroesophageal junction. After this, the endoscopist advanced the gastroscope back into the stomach and proceeded to do any interventions deemed necessary such as biopsies of detected lesions. This ensured that the procedure time measured was standardized and not confounded by the number of additional endoscopic interventions due to detection of more lesions.

Endoscopic scoring system of mucosal visibility
-----------------------------------------------

Before initiation of the study, all the endoscopists were instructed on the endoscopic scoring system which was based on the McNally scoring system (Figure [1](#F1){ref-type="fig"})\[[@B14]\]. Prior to any additional flushes with diluted simethicone solution, the endoscopists evaluated and noted the McNally score for the esophagus, the gastric fundus and body, the gastric antrum and angularis, and the duodenum. The scoring per area was from the range of 1 to 4; 1 if there was no bubble at all, 2 if there were minimal bubbles which the endoscopist had to actively look out for, 3 if the bubbles were obvious but not totally obscuring the view and 4 if the bubbles were so severe that vision is obscured. The total mucosal visibility score (TMVS) was calculated by the sum of scores in all the areas and ranged from 4 to 16.

![Endoscopic scoring system. Score of 1: No bubbles; Score of 2: Minimal bubbles which the endoscopist must actively look for; Score of 3: Foam is obviously present but not severe; Score of 4: Severe foam obscuring vision; Area A: Esophagus; Area B: The antrum and angularis of the stomach; Area C: The body and fundus of the stomach; Area D: Duodenum. TMVS is the sum of the scores of areas A, B, C and D added together. TMVS: Total mucosal visibility score.](WJGPT-7-572-g001){#F1}

Outcomes measured
-----------------

The primary end-point measured was the mean TMVS in the simethicone premedication group and the placebo group respectively. The secondary end-points measured were the mean visibility scores per area, the mean procedure time per group, the mean volume of additional flushes required per group, adverse events reported by the patient or monitoring endoscopy nurses, and the number of gastric lesions reported by the endoscopist.

Statistical analysis
--------------------

We felt that a difference of 2 points in mean TMVS between the two groups would be clinically significant. An earlier study conducted in Thailand had used a similar scoring system and we adopted the standard deviation in their study results for our estimation\[[@B15]\]. The calculated sample size for each group was 24 patients (SD 2.4, 2 sample *t* test, *P* \< 0.05, 80% power). Assuming that the drop-out rate could be around 10%, we aimed to recruit 27 patients per group.

All categorical variables were analysed with Pearson Chi-square test and all continuous variables were analysed with 2-sample *t* test, using SPSS V.19.0 software for Windows (SPSS Inc, Chicago, Illinois, United States). *P* \< 0.05 was deemed statistically significant.

RESULTS
=======

A total of 56 patients were enrolled in the study. One patient withdrew consent on the day of the gastroscopy. Another patient subsequently called to cancel the gastroscopy. The remaining 54 patients completed the study with no adverse events (Figure [2](#F2){ref-type="fig"}) Baseline characteristics of the patients in the 2 groups were similar in terms of mean age, gender, and premedication time (Table [1](#T1){ref-type="table"}). Six experienced endoscopists conducted the gastroscopy for all the patients, 4 of the endoscopists were involved in both groups (Figure [3](#F3){ref-type="fig"}). Before the study, all endoscopists separately scored the TMVS for the endoscopic images of four anonymous participants. They were blinded to the treatment allocation and patient particulars. The scores were tallied by an independent investigator to determine the interobserver agreement which was found satisfactory with a kappa statistic of 0.73.

###### 

Baseline characteristics of the patients *n* (%)

                                                           **Placebo group** **(*n* = 27)**   **Simethicone group** **(*n* = 27)**   ***P* vaule**
  -------------------------------------------------------- ---------------------------------- -------------------------------------- ---------------
  Mean age (yr ± SD)                                       52.9 ± 15.5                        57.7 ± 12.5                            0.215
  Male gender (%)                                          9 (33.3)                           15 (55.6)                              0.1
  Mean premedication time (min:s ± SD)                     41:08 ± 9:56                       44:46 ± 12:36                          0.245
  Indication for gastroscopy                                                                                                         
  Dyspepsia                                                19 (70.4)                          10 (37.0)                              0.014
  Reflux symptoms                                          3 (11.1)                           6 (22.2)                               0.467
  Positive *H. pylori* serology                            0                                  1 (3.7)                                1
  Variceal screen                                          1 (3.7)                            2 (7.4)                                1
  Anemia                                                   4 (14.8)                           3 (11.1)                               1
  Dysphagia                                                0                                  1 (3.7)                                1
  Intestinal metaplasia surveillance                       0                                  3 (11.1)                               0.236
  Cancer surveillance after endoscopic mucosal resection   0                                  1                                      1

*H. pylori: Helicobacter pylori*.

![Workflow of patient enrollment.](WJGPT-7-572-g002){#F2}

![Endoscopist contribution per group.](WJGPT-7-572-g003){#F3}

The mean TMVS was significantly lower in the simethicone group compared to the placebo group (5.78 ± 1.65 for simethicone group, 8.89 ± 1.97 for placebo group, *P* \< 0.001). This improvement in mucosal visibility score was significant for the areas of the stomach (body, fundus, antrum, and angularis) and the duodenum. However, simethicone premedication did not significantly improve mucosal visibility score of the esophagus. The simethicone group also had a shorter mean procedure time (*P* = 0.049) as well as lower mean volume of additional flushes required during gastroscopy (*P* \< 0.001) (Table [2](#T2){ref-type="table"}).

###### 

Study results

                                                               **Placebo group**   **Simethicone group**   ***P* value**
  ------------------------------------------------------------ ------------------- ----------------------- ---------------
  TMVS ± SD                                                    8.89 ± 1.97         5.78 ± 1.65             \< 0.001
  Mean esophagus score ± SD                                    1.59 ± 0.57         1.48 ± 0.57             0.482
  Mean duodenum score ± SD                                     2.26 ± 0.81         1.26 ± 0.53             \< 0.001
  Mean antrum and angularis score ± SD                         2.56 ± 1.05         1.30 ± 0.54             \< 0.001
  Mean body and fundus score ± SD                              2.44 ± 0.97         1.74 ± 0.81             0.006
  Mean volume of additional water flushes required ± SD (mL)   84.81 ± 110.18      3.89 ± 11.46            \< 0.001
  Procedure time ± SD (s)                                      193.67 ± 87.04      154.85 ± 49.07          0.049

TMVS: Total mucosal visibility score.

In the simethicone group, 51.9% of the patients had TMVS of 4 (no bubbles in all areas inspected) to 5 (one area had minimal bubbles), whereas in the placebo group only 3.7% of the patients achieved this (*P* \< 0.001) (Figure [4](#F4){ref-type="fig"}). The number needed to treat (NNT) was 2.1 to avoid a TMVS of 6 or more.

![Percentage of patients with total mucosal visibility score of 4-5 during gastroscopy. TMVS: Total mucosal visibility score.](WJGPT-7-572-g004){#F4}

DISCUSSION
==========

To our knowledge, this is the first study conducted which evaluated the benefit of a very low volume of simethicone monotherapy for gastroscopy preparation, which was compared against a placebo using the McNally scoring method. Prior studies had shown that larger volumes produced better results and a 100 mL solution was generally accepted as the best. Bertoni et al\[[@B10]\] showed in their study that 90 mL solutions were superior to 30 mL solutions when ingested 5 min before the start of gastroscopy. Chang et al\[[@B6]\] showed in their recent study that when ingested within 30 min before gastroscopy, their 100 mL solution consisting of mucolytic and anti-foaming agent resulted in the best mucosal visibility scores. In this study, the premedication time was increased significantly (mean premedication times were 41:08 ± 9:56 min for placebo group and 44:46 ± 12:36 min for simethicone group), which allowed mixing of the simethicone with gastric secretion and swallowed saliva to coat the mucosal surface. This resulted in significant improvement of TMVS compared to placebo (Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). Although the improvement in mucosal visibility scores was not significant for the esophageal area, the mean scores for the esophageal area were already very low to begin with (1.48 ± 0.57 in the simethicone group and 1.59 ± 0.57 in the placebo group). We postulated that this was because of the tubular structure of the esophagus as well as the peristaltic movements of the esophagus allowing mucus and secretions to flow down into the stomach. In additional, our study population is made up of healthy patients who were predominantly undergoing gastroscopy for dyspepsia; only 1 patient had dysphagia and 9 patients had reflux symptoms. This may result in the study population having a better mucosal visibility score in the esophageal area at baseline and explain why low volume simethicone solution did not make much of a difference. There was also significantly lower volume of additional flushes required during gastroscopy if simethicone was given. This, in turn, resulted in a significantly shorter procedure time for mucosal inspection (Figure [7](#F7){ref-type="fig"}). The ideal TMVS was 4 with absolutely no bubbles in all areas. In our study, the NNT to achieve a TMVS of 4 to 5 during gastroscopy was just 2.1.

![Endoscopic images of a patient in the placebo group (total mucosal visibility score 13).](WJGPT-7-572-g005){#F5}

![Endoscopic images of a patient in the simethicone group (total mucosal visibility score 4).](WJGPT-7-572-g006){#F6}

![Correlation between volume of additional water flushes during gastroscopy (mL) and total mucosal inspection time (s).](WJGPT-7-572-g007){#F7}

Our study had two main limitations. Firstly, the study was not powered to investigate for the improvement of gastric lesion detection with enhanced endoscopy techniques. Our study participants were all recruited from the clinics for elective gastroscopies and the findings were predominantly benign functional dyspepsia or non-erosive gastritis which did not require further enhanced imaging as determined by the endoscopist. In order to investigate this aspect, we would have required a much larger study population which will likely require a multi-center collaboration. Secondly, we did not investigate the additional benefit of adding mucolytics to the regime which many other studies had done. This is because N-acetylcysteine is not readily available (it requires prior prescription and collection from the pharmacy by the patient) whereas simethicone is stored at all endoscopy suites and we wanted to find a convenient premedication regime that our endoscopists will be comfortable using.

None of the patients had any adverse event. As the volume of premedication required is only 5 to 6 mL in total, this is likely suitable for use in patients with swallowing dysfunction as such volumes are routinely used as modified water swallowing tests swallowing test\[[@B13]\].
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Applications
------------
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